Alnylam Pharmaceuticals Inc DUL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- €196.30
- Day Range
- €200.10–206.50
- 52-Week Range
- €177.10–417.40
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 133.81M
- Market Cap
- $27.63B
- Volume/Avg
- 5 / 70
Key Statistics
- Price/Earnings (Normalized)
- 30.07
- Price/Sales
- 6.96
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,500
- Website
- https://www.alnylam.com
Competitors
Valuation
|
Metric
|
DUL
|
IONS
|
INCY
|
|---|---|---|---|
Price/Earnings (Normalized) | 30.07 | — | 12.59 |
Price/Book Value | 23.29 | 17.06 | 3.57 |
Price/Sales | 6.96 | 8.45 | 3.98 |
Price/Cash Flow | 22.43 | — | 10.02 |
Price/Earnings
DUL
IONS
INCY
Financial Strength
|
Metric
|
DUL
|
IONS
|
INCY
|
|---|---|---|---|
Quick Ratio | 2.79 | 6.70 | 4.31 |
Current Ratio | 3.05 | 7.89 | 4.59 |
Interest Coverage | 3.12 | −5.82 | 791.55 |
Quick Ratio
DUL
IONS
INCY
Profitability
|
Metric
|
DUL
|
IONS
|
INCY
|
|---|---|---|---|
Return on Assets (Normalized) | 22.09% | −12.57% | 26.83% |
Return on Equity (Normalized) | 149.53% | −75.28% | 35.48% |
Return on Invested Capital (Normalized) | 63.06% | −14.91% | 33.21% |
Return on Assets
DUL
IONS
INCY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|lZ^KL$S | LOCK|C#&J@ | $129B | |||
| Moderna Inc
MRNA
| LOCK|K>PKx^m | LOCK|$&? | $90B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%XS#Zs& | LOCK|&Jf% | $77B | |||
| argenx SE ADR
ARGX
| LOCK|VVfh<#g | LOCK|SwJ | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H$!@?MB | LOCK|lTt | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<Kq%!XZ | LOCK|#^RSk | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|#LS#^t&^ | LOCK|@D?> | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|KDnkpjS | LOCK|gp# | $24B | |||
| Incyte Corp
INCY
| LOCK|&VFd^&k | LOCK|?H | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|tdf^$!$ | LOCK|$s | $14B |
United States